Department of Neuropsychiatry, Fukushima Medical University, Fukushima, Japan.
Psychiatry Clin Neurosci. 2020 May;74(5):289-293. doi: 10.1111/pcn.12984. Epub 2020 Feb 15.
Mismatch negativity (MMN) deficit is one of the most robust and replicable findings in schizophrenia, and primarily reflects deficient functioning of the N-methyl-D-aspartate (NMDA) receptor system. Although the dopamine receptor is known not to modulate MMN over the short term, it is unclear whether the dopamine system affects MMN in the long term.
We explored correlations between MMN and levels of plasma dopamine and serotonin metabolites in 18 patients with schizophrenia psychiatrically evaluated with the Positive and Negative Syndrome Scale (PANSS).
A significant negative correlation exists between MMN amplitude and plasma levels of dopamine metabolites. Plasma serotonin metabolite levels were not correlated with MMN. The PANSS total score and Negative score also showed negative correlations with MMN amplitude.
The usual strong therapeutic blockade of dopamine receptors applied in cases of schizophrenia may reduce MMN over the long term.
错配负波（MMN）缺陷是精神分裂症中最具稳健性和可重复性的发现之一，主要反映了 N-甲基-D-天冬氨酸（NMDA）受体系统功能的缺陷。尽管多巴胺受体在短期内不会调节 MMN，但尚不清楚多巴胺系统是否会长期影响 MMN。
我们通过正性和阴性症状量表（PANSS）对 18 名精神分裂症患者进行精神病学评估，探讨了 MMN 与血浆多巴胺和 5-羟色胺代谢物水平之间的相关性。
MMN 幅度与血浆多巴胺代谢物水平呈显著负相关。血浆 5-羟色胺代谢物水平与 MMN 无相关性。PANSS 总分和阴性评分也与 MMN 幅度呈负相关。
精神分裂症患者通常应用的强烈的多巴胺受体治疗阻断可能会导致 MMN 随时间的推移而减少。
